Quarterly ResultMay 14, 2026, 04:07 PM
ImmuCell Q1 Net Income $1.9M, Sales +28.4% to $10.4M
AI Summary
ImmuCell Corporation reported strong unaudited financial results for the first quarter of 2026, with net income rising to $1.9 million, a $0.5 million increase from Q1 2025. Product sales grew 28.4% to $10.4 million, driven by high seasonal demand and a 3% increase in market share. The company generated $3.4 million in free cash flow, boosting its cash position to $6.8 million, and settled a dispute with a former manufacturer for a $2 million payment intended for capacity expansion.
Key Highlights
- Net income increased to $1.9 million in Q1 2026, up $0.5 million from Q1 2025.
- Product sales grew 28.4% to $10.4 million in Q1 2026.
- Gross margin improved to 45.0% in Q1 2026 from 41.6% in Q1 2025.
- Generated $3.4 million in free cash flow, increasing cash to $6.8 million.
- Gained approximately 3% market share in the U.S. scours biologicals market.
- Manufacturing output increased to over 450,000 units per month in Q1 2026.
- Settled disputes with a former contract manufacturer for a $2 million net payment to ImmuCell.